Cogent Biosciences (COGT) Other Non Operating Income (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Other Non Operating Income of -$140000.0 for Q1 2026, down 2700.0% year-over-year from $5384.6 in Q1 2025, and down 2233.33% quarter-over-quarter from -$6000.0 in Q4 2025.
Cogent Biosciences (COGT) Other Non Operating Income (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Non Operating Income for 10 consecutive years, with -$140000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 2700.0% year-over-year to -$140000.0; the TTM figure through Mar 2026 stood at -$155000.0 (down 107.8% YoY), while the FY2025 annual figure was -$20000.0, down 101.0% from the prior year.
- Other Non Operating Income retreated to -$140000.0 in Q1 2026 per COGT's latest filing, from -$6000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.9 million in Q4 2024 and bottomed at -$140000.0 in Q1 2026.
- Historically, Other Non Operating Income has averaged $314000.0 across 5 years, with a median of $22500.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non Operating Income soared 27928.57% — and 2026, when it plunged 2700.0%.
- Cogent Biosciences' Other Non Operating Income stood at $657000.0 in 2022, then sank by 101.07% to -$7000.0 in 2023, then jumped by 27928.57% to $1.9 million in 2024, then slumped by 100.31% to -$6000.0 in 2025, then sank by 2233.33% to -$140000.0 in 2026.
- Business Quant data shows COGT's Other Non Operating Income at -$140000.0 in Q1 2026, -$6000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,000.00 |
| Mar 31, 2026 | -140,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Jun 30, 2023 | 268,000.00 |
| Mar 31, 2023 | 682,000.00 |
| Dec 31, 2022 | 657,000.00 |
| Sep 30, 2022 | 259,000.00 |
| Jun 30, 2022 | 656,000.00 |
| Mar 31, 2022 | 677,000.00 |
| Dec 31, 2021 | 621,000.00 |
| Sep 30, 2021 | 620,000.00 |
| Jun 30, 2021 | 623,000.00 |